Community Oncology Alliance

Community Oncology Alliance
Name	Community Oncology Alliance
Abbreviation	COA
Formation	2002
Type	Trade association
Headquarters	Washington, D.C.
Region served	United States
Membership	Community oncology practices

Community Oncology Alliance is a United States-based trade association representing independent and community-based oncology practices. The organization engages with federal agencies, congressional committees, patient advocacy groups, pharmaceutical companies, and health systems to influence reimbursement, regulatory, and payment policy affecting oncology care. It convenes stakeholders across cancer care delivery, providing practice resources, policy research, and educational events.

History

The organization was founded in 2002 amid debates over Medicare payment reform involving the Medicare Prescription Drug, Improvement, and Modernization Act of 2003, the Centers for Medicare & Medicaid Services, and oncology reimbursement models. Early interactions involved stakeholders such as the American Society of Clinical Oncology, the National Comprehensive Cancer Network, and the Oncology Nursing Society, positioning the group within broader negotiations over the Medicare Modernization Act and the Physician Fee Schedule. Throughout the 2000s the association responded to proposals from the Office of Inspector General (United States Department of Health and Human Services), participated in rulemaking with the Department of Health and Human Services, and engaged with members of the United States Congress including staff from the House Ways and Means Committee and the Senate Finance Committee. In the 2010s the organization confronted changes tied to the Affordable Care Act, the Protecting Access to Medicare Act of 2014, and the introduction of the Merit-based Incentive Payment System. The organization has since worked alongside organizations such as Blue Cross Blue Shield Association, American Hospital Association, and private payers during debates about the Alternative Payment Model demonstrations and the Center for Medicare and Medicaid Innovation.

Mission and Advocacy

The stated mission centers on preserving access to community-based oncology through advocacy before policymakers such as the White House, the U.S. Department of Health and Human Services, and congressional leadership. It advances policy positions in coalition with groups like the National Rural Health Association, the Cancer Support Community, and the Patient Advocate Foundation. The association emphasizes issues including payment adequacy tied to the Medicare Payment Advisory Commission, site-neutral payment proposals from the Centers for Medicare & Medicaid Services, and drug reimbursement policies shaped by stakeholders such as Pharmaceutical Research and Manufacturers of America and major manufacturers like Roche, Pfizer, and Merck & Co.. It also engages with guideline-setting bodies such as National Comprehensive Cancer Network and research funders like the National Cancer Institute.

Programs and Services

Programs include practice support tools, benchmarking data, continuing medical education in conjunction with organizations like American Society of Clinical Oncology, and quality programs aligned with registries such as the American College of Surgeons Commission on Cancer. Services offered to member practices mirror initiatives of groups like the Association of Community Cancer Centers and include revenue cycle consulting, coding and compliance education relevant to the Health Insurance Portability and Accountability Act of 1996, and operational best practices informed by collaborations with firms such as McKinsey & Company and Deloitte. The association organizes annual conferences that attract speakers from the Food and Drug Administration, the National Institutes of Health, and payer leaders from companies like UnitedHealth Group and Aetna.

Policy and Advocacy Impact

The organization files comments on rulemaking at the Centers for Medicare & Medicaid Services and lobbies Congress through registered entities in Washington, D.C., interacting with committees including the House Energy and Commerce Committee. It has influenced debates over the 340B Drug Pricing Program and site-neutral payment proposals advanced by the Medicare Payment Advisory Commission. The group has supported legislative initiatives introduced by members such as Rep. Anna Eshoo and Sen. Susan Collins on access and reimbursement, and has worked alongside coalitions that include the American Medical Association and specialty societies like American Society for Radiation Oncology. Their policy work extends to issues before the Supreme Court of the United States when litigation affects statutory interpretations relevant to reimbursement.

Membership and Structure

Membership comprises community oncology practices, private practice physicians, and practice administrators, with governance through a board of directors that has included representatives drawn from state oncology societies such as the California Society of Clinical Oncology and the Florida Society of Clinical Oncology. The association operates regional chapters similar to structures used by the American College of Physicians and staff offices in Washington modeled on advocacy operations like those of the American Hospital Association. Committees cover clinical operations, reimbursement, and compliance, interfacing with credentialing entities like the American Board of Internal Medicine and accreditation bodies such as the Commission on Cancer.

Funding and Partnerships

Funding sources include membership dues and sponsorship from pharmaceutical and device companies including Amgen, Bristol-Myers Squibb, and Novartis, and partnerships with foundations like the Robert Wood Johnson Foundation and patient organizations such as Leukemia & Lymphoma Society. The group collaborates on grants and projects with academic centers including Johns Hopkins University and Dana-Farber Cancer Institute, and participates in multi-stakeholder efforts with payers including Cigna and policy organizations like the Kaiser Family Foundation.

Criticism and Controversies

Critics have raised concerns about industry funding and potential conflicts of interest similar to controversies faced by groups such as the American Cancer Society and debates around pharmaceutical influence documented in investigations involving companies like Johnson & Johnson. The association’s positions on the 340B Drug Pricing Program and site-neutral payments have drawn criticism from hospital advocacy groups including the American Hospital Association and from some patient advocates aligned with Patients for Affordable Drugs Now. Questions have also been raised about lobbying disclosures filed with the United States Senate Office of Public Records and the balance between advocacy and clinical guidance amid interactions with regulatory agencies such as the Food and Drug Administration.

Category:Health care trade associations in the United States